143 related articles for article (PubMed ID: 8542599)
21. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
[TBL] [Abstract][Full Text] [Related]
22. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
24. Radiation-induced DNA damage in tumors and normal tissues. I. Feasibility of estimating the hypoxic fraction.
Zhang H; Wheeler KT
Radiat Res; 1993 Oct; 136(1):77-88. PubMed ID: 8210342
[TBL] [Abstract][Full Text] [Related]
25. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.
Evans SM; Hahn SM; Magarelli DP; Koch CJ
Am J Clin Oncol; 2001 Oct; 24(5):467-72. PubMed ID: 11586098
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
27. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.
Teicher BA; Holden SA; Ara G; Dupuis NP; Goff D
Cancer J Sci Am; 1995; 1(1):43-8. PubMed ID: 9166453
[TBL] [Abstract][Full Text] [Related]
28. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.
Mahy P; De Bast M; Gallez B; Gueulette J; Koch CJ; Scalliet P; Grégoire V
Radiother Oncol; 2003 Apr; 67(1):53-61. PubMed ID: 12758240
[TBL] [Abstract][Full Text] [Related]
29. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
Evans SM; Judy KD; Dunphy I; Jenkins WT; Nelson PT; Collins R; Wileyto EP; Jenkins K; Hahn SM; Stevens CW; Judkins AR; Phillips P; Geoerger B; Koch CJ
Cancer Res; 2004 Mar; 64(5):1886-92. PubMed ID: 14996753
[TBL] [Abstract][Full Text] [Related]
30. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion.
Koch CJ; Oprysko PR; Shuman AL; Jenkins WT; Brandt G; Evans SM
Cancer Res; 2002 Jul; 62(13):3626-9. PubMed ID: 12097264
[TBL] [Abstract][Full Text] [Related]
31. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
32. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors.
Salmon HW; Siemann DW
Radiother Oncol; 2004 Dec; 73(3):359-66. PubMed ID: 15588883
[TBL] [Abstract][Full Text] [Related]
33. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing.
Cárdenas-Navia LI; Yu D; Braun RD; Brizel DM; Secomb TW; Dewhirst MW
Cancer Res; 2004 Sep; 64(17):6010-7. PubMed ID: 15342381
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts.
Pinel S; Barberi-Heyob M; Cohen-Jonathan E; Merlin JL; Delmas C; Plenat F; Chastagner P
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):250-9. PubMed ID: 15093922
[TBL] [Abstract][Full Text] [Related]
35. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
36. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
Evans SM; Du KL; Chalian AA; Mick R; Zhang PJ; Hahn SM; Quon H; Lustig R; Weinstein GS; Koch CJ
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1024-31. PubMed ID: 17967299
[TBL] [Abstract][Full Text] [Related]
37. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.
Evans SM; Schrlau AE; Chalian AA; Zhang P; Koch CJ
J Invest Dermatol; 2006 Dec; 126(12):2596-606. PubMed ID: 16810299
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia is important in the biology and aggression of human glial brain tumors.
Evans SM; Judy KD; Dunphy I; Jenkins WT; Hwang WT; Nelson PT; Lustig RA; Jenkins K; Magarelli DP; Hahn SM; Collins RA; Grady MS; Koch CJ
Clin Cancer Res; 2004 Dec; 10(24):8177-84. PubMed ID: 15623592
[TBL] [Abstract][Full Text] [Related]
39. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
Busch TM; Hahn SM; Evans SM; Koch CJ
Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]